Progyny (NASDAQ: PGNY) Price Target Raised Amidst Strong Financial Performance

Font: Financial Modeling Prep  • May 15, 2026

• Investment firm Barclays raised its price target for Progyny (NASDAQ: PGNY) to $27.00, maintaining an "Overweight" rating, signaling strong analyst confidence.
• Progyny reported robust Q1 2026 financial results, with earnings of $0.50 per share beating estimates and record revenue of $328.5 million.
• The company demonstrates strong demand for its fertility and family building solutions and has returned value to shareholders through share repurchases.

Progyny is a benefits management company that provides fertility and family building solutions for employers. It operates in the medical sector and is considered a top-ranked stock, as highlighted by Zacks Investment Research. The company is sometimes mentioned alongside other medical stocks like DaVita (NYSE: DVA) and Globus Medical (NYSE: GMED).

On May 15, 2026, investment firm Barclays raises its price target for Progyny to $27.00 from a previous target of $23.00. Barclays also maintains its "Overweight" rating on the stock. An "Overweight" rating suggests that an analyst believes a stock will perform better than the average return of other stocks in its sector.

This positive analyst view is supported by strong financial results. For the first quarter of 2026, Progyny reports earnings of $0.50 per share, beating the Zacks Consensus Estimate of $0.44. The company also posts record revenue of $328.5 million, surpassing the $324.04 million from the same quarter a year ago.

This performance continues a positive trend, as Progyny now surpasses analyst estimates for four consecutive quarters. As highlighted by GlobeNewswire, the company notes strong early selling season activity. This reflects robust demand for its women's health and family building solutions, with high member engagement for its services.

Progyny also returns value to its shareholders, having repurchased 8.8 million shares since November of the previous year. At the time of the rating, the stock trades at $23.25. This is within a 52-week range of $16.10 and $28.75, giving it a market capitalization of $1.82 billion.